Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2004 | 1 |
2008 | 1 |
2021 | 1 |
2022 | 1 |
2024 | 0 |
Search Results
3 results
Results by year
Filters applied: . Clear all
Page 1
Cost-effectiveness of treatment for acute childhood idiopathic thrombocytopenic purpura (ITP)--a systematic review.
J Int Med Res. 2008 May-Jun;36(3):572-8. doi: 10.1177/147323000803600324.
J Int Med Res. 2008.
PMID: 18534141
Free article.
Review.
The cost-effectiveness of treatment for acute paediatric idiopathic thrombocytopenic purpura (ITP) was assessed to provide evidence for health-care decision making and rational drug use. ...In comparison, the quality of the Chinese studies was low and long-te …
The cost-effectiveness of treatment for acute paediatric idiopathic thrombocytopenic purpura (ITP) was assessed to prov …
Clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole in the secondary prevention of occlusive vascular events: a systematic review and economic evaluation.
Jones L, Griffin S, Palmer S, Main C, Orton V, Sculpher M, Sudlow C, Henderson R, Hawkins N, Riemsma R.
Jones L, et al.
Health Technol Assess. 2004 Oct;8(38):iii-iv, 1-196. doi: 10.3310/hta8380.
Health Technol Assess. 2004.
PMID: 15461876
Free article.
Review.
OBJECTIVES: To examine the clinical effectiveness and cost-effectiveness of two alternative antiplatelet agents, clopidogrel and modified-release (MR)-dipyridamole, relative to prophylactic doses of aspirin for the secondary prevention of occlusive vascular e …
OBJECTIVES: To examine the clinical effectiveness and cost-effectiveness of two alternative antiplatelet agents, clopid …
Item in Clipboard
Thrombopoietin receptor agonists and rituximab for treatment of pediatric immune thrombocytopenia: A systematic review and meta-analysis of prospective clinical trials.
Ayad N, Grace RF, Al-Samkari H.
Ayad N, et al.
Pediatr Blood Cancer. 2022 Mar;69(3):e29447. doi: 10.1002/pbc.29447. Epub 2021 Dec 28.
Pediatr Blood Cancer. 2022.
PMID: 34962697
BACKGROUND: Children with immune thrombocytopenia (ITP) may require second-line ITP therapies. The high remission rate in pediatric patients, need for extended-duration use of thrombopoietin receptor agonists (TPO-RAs), drug adherence, potential side effects, monitoring, a …
BACKGROUND: Children with immune thrombocytopenia (ITP) may require second-line ITP therapies. The high remission rate in pediatric p …
Item in Clipboard
Cite
Cite